ATE276740T1 - Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten - Google Patents

Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten

Info

Publication number
ATE276740T1
ATE276740T1 AT96926158T AT96926158T ATE276740T1 AT E276740 T1 ATE276740 T1 AT E276740T1 AT 96926158 T AT96926158 T AT 96926158T AT 96926158 T AT96926158 T AT 96926158T AT E276740 T1 ATE276740 T1 AT E276740T1
Authority
AT
Austria
Prior art keywords
lung
acceptable salt
sample
mucus
composition
Prior art date
Application number
AT96926158T
Other languages
English (en)
Inventor
Richard C Boucher Jr
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE276740T1 publication Critical patent/ATE276740T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96926158T 1995-07-31 1996-07-24 Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten ATE276740T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/509,052 US5628984A (en) 1995-07-31 1995-07-31 Method of detecting lung disease
PCT/US1996/012377 WO1997005195A1 (en) 1995-07-31 1996-07-24 Method of detecting lung disease

Publications (1)

Publication Number Publication Date
ATE276740T1 true ATE276740T1 (de) 2004-10-15

Family

ID=24025091

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926158T ATE276740T1 (de) 1995-07-31 1996-07-24 Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten

Country Status (17)

Country Link
US (4) US5628984A (de)
EP (1) EP0841900B1 (de)
JP (2) JP3623237B2 (de)
KR (1) KR100283306B1 (de)
CN (1) CN1121441C (de)
AT (1) ATE276740T1 (de)
AU (1) AU705528B2 (de)
BR (1) BR9610059A (de)
CA (1) CA2226892A1 (de)
DE (1) DE69633449T2 (de)
ES (1) ES2229281T3 (de)
IL (1) IL122803A0 (de)
MX (1) MX9800933A (de)
NO (1) NO980279L (de)
NZ (1) NZ313864A (de)
WO (1) WO1997005195A1 (de)
ZA (1) ZA966425B (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948768A (en) * 1995-04-13 1999-09-07 Milkhaus Laboratory Treatment of otitis media by sublingual administration of DNA
US6096721A (en) * 1995-04-13 2000-08-01 Milkhaus Laboratory, Inc. Method for treating mucositis by sublingual administration of DNA
AU716486B2 (en) * 1995-04-13 2000-02-24 Milkhaus Laboratory, Inc. Methods for treating respiratory disease
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
US6998121B2 (en) 2003-01-23 2006-02-14 Milkhaus Laboratory, Inc. Method of treatment of connective tissue disorders by administration of streptolysin O
TW593331B (en) * 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
ATE261982T1 (de) 1997-07-25 2004-04-15 Inspire Pharmaceuticals Inc Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
CA2300146A1 (en) * 1997-08-29 1999-03-04 Richard C. Boucher, Jr. Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
JP2002532520A (ja) * 1998-12-22 2002-10-02 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 気道病治療および気道用薬剤送達のための化合物および方法
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
JP2002537329A (ja) * 1999-02-26 2002-11-05 インスパイアー ファーマシューティカルズ，インコーポレイティド 特定のウリジン、アデニン及びシチジン二リン酸並びにそれらの類似体による粘膜水和の促進方法
AU782966B2 (en) * 1999-06-08 2005-09-15 University Of Iowa Research Foundation, The Compounds and methods to enhance RAAV transduction
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
JP2005508297A (ja) 2001-06-25 2005-03-31 インスパイアー ファーマシューティカルズ，インコーポレイティド Ｐ２ｙプリン受容体作用物質による関節潤滑
JP3823162B2 (ja) * 2001-07-31 2006-09-20 株式会社エイアンドティー 臨床検査分析装置、臨床検査分析方法および臨床検査分析プログラム
AR037263A1 (es) * 2001-11-06 2004-11-03 Inspire Pharmaceuticals Inc Uso de una formulacion farmaceutica para la manufactura de un medicamento para el tratamiento o prevencion de enfermedades inflamatorias
US20060196365A1 (en) * 2001-12-11 2006-09-07 Garman Michael H Combined water cooler and hot beverage maker
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7435724B2 (en) * 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1531795A4 (de) 2002-05-02 2011-02-23 Harvard College Formulierungen zur begrenzung der ausbreitung von lungeninfektionen
US20050220720A1 (en) * 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
US7629312B2 (en) 2003-01-23 2009-12-08 Milkhaus Laboratory, Inc. Method of treatment of tendonitis by administration of streptolysin O
JP2006521825A (ja) * 2003-03-31 2006-09-28 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ導入を高めるための化合物および方法
WO2004112687A2 (en) * 2003-06-26 2004-12-29 Biotron Limited Antiviral acylguanidine compounds and methods
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7825279B2 (en) * 2003-11-24 2010-11-02 The University Of North Carolina At Chapel Hill Fused ring dicationic anti-protozoan agents and their prodrugs
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
WO2005086754A2 (en) * 2004-03-08 2005-09-22 Georgia State University Research Foundation, Inc. Dicationic compounds for activity against trichomonas vaginalis
US20070099968A1 (en) * 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
US20060199768A1 (en) * 2005-03-07 2006-09-07 University Of North Carolina At Chapel Hill Inhibitors of RecA activities for control of antibiotic-resistant bacterial pathogens
AU2006201739A1 (en) * 2005-05-05 2006-11-23 The University Of North Carolina At Chapel Hill Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles
US20070053844A1 (en) * 2005-05-18 2007-03-08 Pulmatrix Inc. Formulations for alteration of biophysical properties of mucosal lining
US7964619B2 (en) 2005-06-03 2011-06-21 The University Of North Carolina At Chapel Hill Teraryl components as antiparasitic agents
AU2006202083A1 (en) 2005-06-03 2006-12-21 Reto Brun Linear dicationic terphenyls and their aza analogues as antiparasitic agents
US20100249175A1 (en) * 2005-12-02 2010-09-30 Wilson W David Dicationic compounds which selectively recognize G-quadruplex DNA
JP2009535034A (ja) * 2006-04-28 2009-10-01 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン 哺乳動物細胞のパルボウイルス形質導入を調節若しくはウイルス感染を変えるための方法および化合物、ウイルス受容体若しくは共受容体の同定方法
US20080260863A1 (en) * 2007-04-20 2008-10-23 Pre Holding, Inc. Compositions for mucociliary clearance and methods for administering same
US8088385B2 (en) 2007-06-18 2012-01-03 University Of Louisville Research Foundation Inc. PFKB3 inhibitor for the treatment of a proliferative cancer
US20100280098A1 (en) * 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
AU2008310734B2 (en) 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
US20100331368A1 (en) * 2007-10-17 2010-12-30 Tidwell Richard R 2,5-diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents
KR20100135886A (ko) 2008-04-09 2010-12-27 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 액틴 세포 골격의 재배열 및 세포간 갭 형성을 조절하는 방법
AU2009298367A1 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
JP2012504645A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物
AU2010229668C1 (en) 2009-03-26 2016-09-15 Pulmatrix Operating Co., Inc. Dry powder formulations and methods for treating pulmonary diseases
ES2561216T3 (es) 2009-05-13 2016-02-25 The University Of North Carolina At Chapel Hill Inhibidores de cinasas dependientes de ciclina y procedimientos de uso
EP2454227B1 (de) 2009-07-13 2020-08-19 Patheon API Services Inc. Prostanoid-synthese
JP5770181B2 (ja) 2009-07-24 2015-08-26 ユニバーシティ オブ テネシー リサーチ ファウンデーション 抗結核剤としてのスペクチナミド類
CN102596010A (zh) * 2009-08-10 2012-07-18 P2科学有限公司 用于诊断狭窄和其他血流受限之病症的utp
WO2011161212A1 (en) * 2010-06-23 2011-12-29 P2-Science Aps Combined flow directed intraarterial microcatheter for the infusion of hyperemic agent and concomitant pressure measurements for diagnostic purposes
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012044736A1 (en) 2010-09-29 2012-04-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
PT3470057T (pt) 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
EP2640394A4 (de) 2010-11-17 2015-02-25 Univ North Carolina Schutz von nierengewebe vor ischämie durch die hemmung der proleverativen kinasen cdk4 und cdk6
WO2012170677A1 (en) * 2011-06-07 2012-12-13 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
CA2865972C (en) 2012-02-29 2022-01-04 Pulmatrix, Inc. Inhalable dry powders
US9833207B2 (en) 2012-08-08 2017-12-05 William Harrison Zurn Analysis and clearing module, system and method
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
BR112015014178A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida
US9962533B2 (en) 2013-02-14 2018-05-08 William Harrison Zurn Module for treatment of medical conditions; system for making module and methods of making module
CN105407889B (zh) 2013-03-15 2018-06-01 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
CN107417691B (zh) 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
JP6488472B2 (ja) 2013-09-30 2019-03-27 パテオン エーピーアイ サービシーズ インコーポレイテッドＰａｔｈｅｏｎ Ａｐｉ Ｓｅｒｖｉｃｅｓ Ｉｎｃ． メタセシスを用いるプロスタグランジンおよびプロスタグランジン中間体の新規合成経路
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104306028B (zh) * 2014-09-26 2016-08-17 张清玲 一种用于呼吸道细菌16S rRNA基因序列检测的痰液收集方法
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340983B1 (de) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl und heterocyclische verbindungen zur behandlung von immun- und entzündungserkrankungen
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
IL261642B2 (en) 2016-03-07 2026-01-01 Univ Iowa Res Found AAV-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
JP2019520379A (ja) 2016-07-01 2019-07-18 ジー１ セラピューティクス， インコーポレイテッド ピリミジン系の抗増殖剤
US10413583B2 (en) 2016-11-30 2019-09-17 The University Of Chicago Synthetic substrates for enzymes that catalyze reactions of modified cysteines and related methods
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
IL303696B2 (en) 2017-03-01 2025-02-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
GB2604314A (en) 2017-09-22 2022-09-07 Nerudia Ltd Device, system and method
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
US11541120B2 (en) 2017-12-05 2023-01-03 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
BR112021004263A2 (pt) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. formas mórficas de danicopano
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
CN113195472A (zh) 2018-12-17 2021-07-30 艾其林医药公司 用于治疗补体介导的病症的靶向给药
WO2020198062A1 (en) 2019-03-22 2020-10-01 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
EP4153597B1 (de) 2020-05-19 2025-09-10 Pharmacosmos Holding A/S Cyclinabhängige kinasehemmende verbindungen zur behandlung von medizinischen erkrankungen
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055465A (en) * 1962-09-27 1967-01-18 Vantorex Ltd Allergenic aerosol compositions
BE639386A (de) * 1962-10-30
US4132600A (en) * 1977-06-01 1979-01-02 Massachusetts Institute Of Technology Enzymatic noninvasive method for detecting cancer
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
FR2571257A1 (fr) * 1984-08-06 1986-04-11 Gros Pierre Composition destinee a l'humidification de la muqueuse rhino-pharyngee
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US4950477A (en) * 1988-08-23 1990-08-21 Memorial Hospital For Cancer And Allied Dieseas Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
EP0517573A1 (de) * 1991-06-05 1992-12-09 Synthelabo Pharmazeutische Zusammensetzungen zur Behandlung von Atemwegserkrankungen
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease

Also Published As

Publication number Publication date
AU705528B2 (en) 1999-05-27
JP3623237B2 (ja) 2005-02-23
WO1997005195A1 (en) 1997-02-13
EP0841900A4 (de) 1998-06-10
CN1191553A (zh) 1998-08-26
JPH11509759A (ja) 1999-08-31
CA2226892A1 (en) 1997-02-13
KR19990036011A (ko) 1999-05-25
DE69633449D1 (de) 2004-10-28
JP2003073280A (ja) 2003-03-12
US5628984A (en) 1997-05-13
IL122803A0 (en) 1998-09-16
BR9610059A (pt) 1999-03-02
DE69633449T2 (de) 2006-04-27
EP0841900B1 (de) 2004-09-22
US5902567A (en) 1999-05-11
CN1121441C (zh) 2003-09-17
US6214536B1 (en) 2001-04-10
AU6639996A (en) 1997-02-26
NZ313864A (en) 2000-04-28
NO980279D0 (no) 1998-01-21
ES2229281T3 (es) 2005-04-16
US6133247A (en) 2000-10-17
ZA966425B (en) 1997-02-19
EP0841900A1 (de) 1998-05-20
MX9800933A (es) 1998-05-31
NO980279L (no) 1998-01-21
KR100283306B1 (ko) 2001-03-02

Similar Documents

Publication Publication Date Title
ATE276740T1 (de) Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten
US5763447C1 (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
JP2000514461A (ja) ウリジン・トリホスフェート及び関連化合物による副鼻腔炎の治療方法
ATE225663T1 (de) Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
EP1014996A4 (de) Zubereitung enthaltende saccharide und methoden zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
ATE335492T1 (de) Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen
ID23375A (id) Metode pengobatan penyakit mata kering dengan agonist-agonist reseptor purinergik
JPH09501413A (ja) 滞留肺分泌物の治療方法
DE69822482D1 (de) Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
DK0630230T3 (da) Farmaceutiske inhaleringspræparater
Rubin et al. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis
CA2240717A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
Puchelle et al. Effect of the mucoregulator S-carboxy-methyl-cysteine in patients with chronic bronchitis
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
EP0666985A1 (de) Verdichtungsprüfung zur bewertung einer therapie für eine atmungskrankheit.
Slocombe et al. Evaluation of ivermectin against later fourth-stage Strongylus vulgaris in ponies at two and five weeks after treatment
KR890012942A (ko) 5-치환된 오르니틴 유도체
Fluur et al. Gout in the temporomandibular joint: report on a case
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체
Buss et al. Visceral herpesvirus infections in leukemic patients receiving cytarabine
Braga et al. Preliminary data on the action of nesosteine, a mucomodifying drug, on mucociliary transport
RU94016314A (ru) Способ пластики-задне-боковой стенки реконструированной гортани
Kuznetsov et al. Case of Kawasaki's disease in the maritime territory
Gewirtz The intravenous drug abuse patient
Bishara et al. Lichenoid reaction in bone marrow transplants suffering from chronic GVHD is associated with HLA-DQW1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties